Tumor News and Research

RSS

Pediatric oncologist describes current state of science in combating neuroblastoma

Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.

15 Jun 2010

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.

15 Jun 2010

Fluorescent cancerous tumors for early detection

Researchers at the Ecole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique- already in practice in Europe - for the American market. Under the name Cysview-, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

14 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

Australian rainforests may provide potential cancer cure

Queensland scientists have discovered a drug to cure cancer that has effectively worked in animals and is to be tried on humans in the next phase of trials. This drug is plant-derived and is called EBC-46 for trial purposes. The plant from which it is obtained is found in the Australian tropical rainforest. The drug has shown to reduce inoperable tumors in 150 dogs, cats and horses and a ferret to a significant extent. The drug was developed over the past six years from the seed of a rainforest plant found in the Atherton Tablelands. Scientists had cultivated their own plantation of the plant since forming the company QBiotics Limited in 2004.

14 Jun 2010

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

The College of American Pathologists and the American Society of Clinical Oncology today issued a joint guideline aimed at improving the accuracy of immunohistochemistry testing for the expression status of estrogen and progesterone receptors in breast cancer. The two groups conducted a systematic review of medical research literature in partnership with Cancer Care Ontario to develop the recommendations.

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

Uncork the Cure to contribute funds for children's brain tumor research

Uncork the Cure – a festival involving wine, food and music – will contribute funds for research into the causes of and cure for children's gliomas or brain tumors.

11 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

A breakthrough external beam radiotherapy technology that is fast, precise, and has optimal dose delivery to targeted tumors while limiting damage to surrounding normal tissue, is the latest radiotherapy weapon that cancer specialists are using at Stony Brook University Medical Center to treat patients.

11 Jun 2010

Ashikari Breast Center to participate in TARGiT intra-operative radiotherapy trial

The Ashikari Breast Center at The Dobbs Ferry Pavilion of St. John's Riverside Hospital today announced its participation in two new groundbreaking studies that may alter the care for early breast cancer.

11 Jun 2010

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

The p53 gene has been a well-documented player in the prevention of tumors. It is considered the most frequently mutated gene in human tumors with more than half harboring p53 mutations (Bennett et al., 1999). These mutations often can be caused by disruption in normal p53 function.

11 Jun 2010

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.

11 Jun 2010

Bevacizumab increases risk for proteinuria in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab (Avastin) may be at an increased risk of severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment. This conclusion stems from a study of more than 12,000 patients by Shenhong Wu, M.D., Ph.D., Principal Investigator, and colleagues at Stony Brook University Medical Center. Their findings are reported in online June 10 in the Journal of the American Society Nephrology (JASN).

11 Jun 2010

WaferGen announces microRNA, oncology gene panels for SmartChip Real-Time PCR System

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced the availability of two gene expression profiling panels for the SmartChip Real-Time PCR System that will enable microRNA and cancer pathway profiling capability.

10 Jun 2010

Tumor News and Research

Pediatric oncologist describes current state of science in combating neuroblastoma

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Fluorescent cancerous tumors for early detection

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Australian rainforests may provide potential cancer cure

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

Chiasma successfully completes Phase I clinical study of Octreolin

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

Uncork the Cure to contribute funds for children's brain tumor research

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

Ashikari Breast Center to participate in TARGiT intra-operative radiotherapy trial

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Bevacizumab increases risk for proteinuria in cancer patients

WaferGen announces microRNA, oncology gene panels for SmartChip Real-Time PCR System

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News